Julia Gallwitz
Aseptic processing remains one of the most challenging and closely scrutinized areas in pharmaceutical manufacturing. Using Redica Systems' global inspection and enforcement database spanning FDA, EMA/MHRA, and other PIC/S member agencies, this presentation analyzes compliance findings from 2022 to the present to highlight both persistent challenges and emerging risks in sterile manufacturing.Key themes include environmental monitoring and contamination control strategies, aseptic technique and human factors, sterilization validation, gowning and operator qualification, airflow visualization and smoke studies, and cleaning and disinfection effectiveness. We will also examine how regulatory expectations have shifted following the implementation of the revised EU GMP Annex 1, with particular attention to contamination control strategy and the adoption of barrier technologies.To illustrate these broader global trends, FDA enforcement serves as a case study. Sterility-related issues account for over 40% of production observations in 483s and over half of production deficiencies in Warning Letters. Inspections citing sterility issues were far more likely to escalate. Viewed alongside inspection findings from EMA and PIC/S agencies, these insights will give attendees a clear view of the compliance landscape and how global regulators are converging-or diverging-on expectations for sterile manufacturing.